Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2013 02:30 ET | Source: Active Biotech

Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sweden, November 4, 2013 - Active...
November 04, 2013 02:30 ET | Source: Active Biotech

Active Biotechs partner Teva startar ytterligare en klinisk studie i multipel skleros

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, Sverige den 4 november 2013 - Active...
October 09, 2013 01:36 ET | Source: Active Biotech

Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study

LUND, Sweden and PARIS, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Active Biotech, under the terms of ...
October 09, 2013 01:30 ET | Source: Active Biotech

Active Biotech erhåller delmålsbetalning från Ipsen för studien 10TASQ10

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Avtalsenlig delmålsbetalning om 12 miljoner EUR ...
October 09, 2013 01:30 ET | Source: Active Biotech

Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Milestone payment of 12 million euros under the...
October 04, 2013 09:36 ET | Source: Active Biotech

New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

JERUSALEM and LUND, Sweden, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today the presentation of...
October 04, 2013 09:30 ET | Source: Active Biotech

New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Pooled Data Analysis of Phase III ALLEGRO and...
October 04, 2013 09:30 ET | Source: Active Biotech

Nya data presenterade på 29th ECTRIMS Congress stärker ytterligare laquinimods kliniska profil vad gäller sjukdomsutveckling och inflammation vid multipel skleros

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Analys av samlade data från de båda fas...
October 01, 2013 08:00 ET | Source: Active Biotech

En ny explorativ fas III-analys visar att den orala läkemedelskandidaten laquinimod för behandling av multipel skleros kan minska skador på hjärnvävnad orsakade av neurodegeneration

En förplanerad analys av över 1000 patienter, publicerad online i the Journal of Neurology, Neurosurgery & Psychiatry, påvisar fördelarna med laquinimod-behandling vid neurodegeneration...
October 01, 2013 08:00 ET | Source: Active Biotech

Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration

Pre-planned analysis of over 1,000 patients published online in the Journal of Neurology, Neurosurgery & Psychiatry demonstrates the benefits of laquinimod on neurodegeneration...